2263 related articles for article (PubMed ID: 24778419)
1. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
Noman MZ; Desantis G; Janji B; Hasmim M; Karray S; Dessen P; Bronte V; Chouaib S
J Exp Med; 2014 May; 211(5):781-90. PubMed ID: 24778419
[TBL] [Abstract][Full Text] [Related]
2. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
3. Targeting hypoxia at the forefront of anticancer immune responses.
Noman MZ; Chouaib S
Oncoimmunology; 2014 Dec; 3(12):e954463. PubMed ID: 25964858
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
5. HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia.
Qiang L; Hong L; Jian X; Zhanlin Z
Int Immunopharmacol; 2023 May; 118():110010. PubMed ID: 36924563
[TBL] [Abstract][Full Text] [Related]
6. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
7. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia.
Ding XC; Wang LL; Zhang XD; Xu JL; Li PF; Liang H; Zhang XB; Xie L; Zhou ZH; Yang J; Weichselbaum RR; Yu JM; Hu M
J Hematol Oncol; 2021 Jun; 14(1):92. PubMed ID: 34118979
[TBL] [Abstract][Full Text] [Related]
8. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
9. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.
Pinton L; Solito S; Damuzzo V; Francescato S; Pozzuoli A; Berizzi A; Mocellin S; Rossi CR; Bronte V; Mandruzzato S
Oncotarget; 2016 Jan; 7(2):1168-84. PubMed ID: 26700461
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
11. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
Corzo CA; Condamine T; Lu L; Cotter MJ; Youn JI; Cheng P; Cho HI; Celis E; Quiceno DG; Padhya T; McCaffrey TV; McCaffrey JC; Gabrilovich DI
J Exp Med; 2010 Oct; 207(11):2439-53. PubMed ID: 20876310
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
13. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
[TBL] [Abstract][Full Text] [Related]
14. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
[TBL] [Abstract][Full Text] [Related]
15. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.
Tawadros AIF; Khalafalla MMM
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1063-S1069. PubMed ID: 30539847
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210.
Noman MZ; Janji B; Hu S; Wu JC; Martelli F; Bronte V; Chouaib S
Cancer Res; 2015 Sep; 75(18):3771-87. PubMed ID: 26206559
[TBL] [Abstract][Full Text] [Related]
17. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
18. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
[TBL] [Abstract][Full Text] [Related]
20. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
